Measuring Carotid Plaque Burden: A Smarter Way to Assess Stroke Risk and Guide Treatment

Table of Contents

• Key Points
• Background: Why Your Carotid Arteries Matter
• Understanding Carotid Plaque and Atherosclerosis
• Three Ways to Measure Plaque Burden
• How This Review Was Conducted
• Key Findings: Four Major Uses of Plaque Burden Measurement
• Why Plaque Burden Is Superior to IMT
• Clinical Implications for Patients
• Limitations to Consider
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Carotid plaque burden directly predicts stroke and heart attack risk better than traditional IMT measurement.
• Plaque burden is measured as total plaque area (TPA), total plaque volume (TPV), or vessel wall volume (VWV).
• Higher plaque burden warrants aggressive treatment; low plaque burden may mean lower risk than blood tests suggest.
• With intensive treatment, plaque can stabilize or regress, and repeat ultrasound or MRI can track changes.
• Ask your doctor if carotid plaque measurement is available and what your numbers mean for your care.

Background: Why Your Carotid Arteries Matter

Every time your heart beats, it pumps oxygen-rich blood toward your brain through two large blood vessels on either side of your neck called the carotid arteries. You can actually feel your carotid pulse by gently pressing the sides of your neck, just below the jawline.

These arteries are critical pathways—and when they become narrowed or blocked by a waxy substance called plaque, the consequences can be devastating. The condition that causes this buildup is called atherosclerosis, a disease in which cholesterol, fat, calcium, and inflammatory cells accumulate inside the artery walls.

When plaque in a carotid artery ruptures, it can form a blood clot that travels to the brain, causing a stroke. For this reason, assessing how much plaque is present—known as plaque burden—is one of the most important things a doctor can do to evaluate a patient's stroke risk.

In October 2020, Dr. J. David Spence, a leading stroke prevention researcher and director of the Stroke Prevention & Atherosclerosis Research Centre at the Robarts Research Institute in London, Ontario, Canada, published a comprehensive review in the journal Current Opinion in Lipidology. The review examines the state of the art in measuring carotid plaque burden and makes a strong case for a major shift in how doctors assess vascular risk.

Understanding Carotid Plaque and Atherosclerosis

To understand plaque burden, it helps to understand what plaque actually is. Atherosclerotic plaque is not simply a matter of "clogged pipes." It is a complex biological process involving inflammation, cholesterol buildup, and changes in the artery wall itself.

Plaque forms over many decades. Early on, the inner layer of the artery wall (the intima) thickens. Later, deposits of cholesterol and fat accumulate, and the body responds with inflammatory cells. Over time, the plaque may calcify, become unstable, or grow large enough to significantly narrow the artery.

Once plaque narrows a carotid artery by more than about 50%, the risk of stroke rises substantially. However, even small plaques can be dangerous if they are inflamed or prone to rupture. This is why measuring the total amount of plaque—rather than just the degree of narrowing—is so valuable.

The carotid arteries are particularly important because they are a common and easily accessible site for atherosclerosis. Ultrasound can visualize them safely, quickly, and without radiation, making them an ideal "window" into the health of the body's arteries as a whole.

Three Ways to Measure Plaque Burden

The review describes three main methods of measuring plaque burden, each capturing a slightly different aspect of the disease:

• Total Plaque Area (TPA): Using standard two-dimensional ultrasound, a technician scans the carotid arteries and measures the cross-sectional area of every plaque visible. These individual areas are added together to give a single number, expressed in square millimeters (mm²). TPA is a simple, well-validated measurement that has been used in research and clinical practice for many years.
• Total Plaque Volume (TPV): Using three-dimensional (3D) ultrasound, the volume of all plaque can be calculated in cubic millimeters (mm³). Because it captures the full three-dimensional extent of the disease, TPV is more sensitive than TPA at detecting small changes in plaque over time—a key advantage when tracking whether a treatment is working.
• Vessel Wall Volume (VWV): Using magnetic resonance imaging (MRI), the entire vessel wall is measured, which includes both the plaque burden and any generalized wall thickening. Because VWV can detect changes in the artery wall even before a distinct plaque has formed, it is especially useful for patients who have no plaque but may still be in the early stages of atherosclerosis.

The author emphasizes that VWV can be measured in persons with no plaque as an alternative to IMT, allowing early disease detection in a broader range of patients.

How This Review Was Conducted

This article is a review article, not a new clinical trial. In medical publishing, a review gathers together findings from many individual studies and synthesizes them into an overall picture of the current evidence.

The journal Current Opinion in Lipidology invites recognized experts to write these reviews, which are published each year alongside commentaries and original research. Dr. Spence has spent decades researching atherosclerosis and stroke prevention, and his review reflects both the published scientific literature and insights from his own extensive research program at Western University.

Because this is an expert review rather than a single study, it does not report one specific patient population or set of results. Instead, it draws conclusions across multiple lines of evidence—from genetics, drug trials, imaging research, and clinical outcomes studies—to make a broader argument about how plaque measurement should be used.

Key Findings: Four Major Uses of Plaque Burden Measurement

The review identifies four major uses of plaque burden measurement. Each of these applications has direct or indirect benefits for patients.

1. Risk stratification (predicting who will have a stroke or heart attack). Plaque burden is a powerful predictor of cardiovascular events. The more plaque a person has, the higher their risk of stroke, heart attack, and other complications. Measuring plaque burden helps doctors identify which patients need more aggressive prevention strategies and which patients may be at lower risk than their other risk factors suggest.
2. Research into the genetics and biology of atherosclerosis. Because plaque burden is a more accurate measure of disease than older methods, it is helping scientists identify genes that contribute to—or protect against—atherosclerosis. Family studies using TPA as a precise "phenotype" (a measurable characteristic of the disease) can reveal inherited patterns that would be missed with cruder measurements. This research may eventually lead to new treatments and personalized risk assessment.
3. Measuring the effects of new therapies for atherosclerosis. Pharmaceutical companies and academic researchers can use TPA or TPV to test whether a new drug slows, halts, or even reverses plaque buildup. Because plaque volume changes measurably over months rather than years, these measurements allow smaller and shorter clinical trials than those that wait for heart attacks or strokes to occur. This accelerates the development of new treatments.
4. Treatment of high-risk patients with severe atherosclerosis. When a patient has a high plaque burden, doctors can intensify therapy—for example, adding medications, lowering LDL ("bad") cholesterol targets, or tightening blood pressure goals. Serial measurements can then track whether the treatment is actually shrinking or stabilizing the plaque, allowing doctors to adjust therapy in real time.

These four uses are interconnected. Better measurement drives better research; better research produces better treatments; and better treatments can be monitored with the same measurements.

Why Plaque Burden Is Superior to IMT

One of the most striking conclusions of the review is stated plainly by the author: "Measurement of plaque burden is far superior to measurement of carotid intima-media thickness (IMT) in many ways, and should replace it."

Carotid intima-media thickness (IMT) is an older ultrasound technique that has been used for decades to assess cardiovascular risk. It measures the combined thickness of the two innermost layers of the carotid artery wall—the intima and the media—in millimeters.

While IMT was a reasonable research tool in its time, the review highlights several major limitations:

• IMT measures only the thickness of the artery wall at a single point, which can miss the actual plaque that causes strokes.
• IMT changes very slowly over time, making it difficult to detect whether a treatment is working.
• It is a weaker predictor of cardiovascular events than direct plaque measurement.
• The small changes measured by IMT are prone to measurement error and may not reflect the biology of atherosclerosis as accurately.

By contrast, measuring the plaque itself directly captures the disease process that leads to strokes. The author argues that plaque burden should replace IMT and that vessel wall volume (VWV) is the appropriate alternative for persons who have no plaque yet—providing the early detection capability that IMT was originally valued for.

Clinical Implications for Patients

The take-home message for patients is that measuring plaque burden can help doctors make better treatment decisions than relying on traditional risk calculators or IMT alone.

If your doctor measures your carotid plaque burden and finds a high level, that is an important warning sign. It means the disease process is already active in your arteries, and aggressive prevention measures—such as statin therapy, blood pressure control, and lifestyle changes—are warranted regardless of your cholesterol numbers or other risk scores.

Conversely, if your plaque burden is low, you may be at lower risk than your blood tests alone would suggest, which could help avoid unnecessary medication.

For patients already on treatment, repeat measurements of TPA or TPV can show whether the therapy is working. The author's research program has demonstrated that plaque can stabilize and even regress when cardiovascular risk factors are intensively treated. Seeing measurable improvement on a scan can also be highly motivating for patients trying to sustain diet, exercise, and medication habits.

Finally, the genetics research described in the review may eventually enable doctors to identify people at elevated genetic risk before they develop significant plaque—opening the door to earlier, more personalized prevention.

Limitations to Consider

While the case for plaque burden measurement is strong, there are important limitations to keep in mind.

First, plaque burden measurement requires specialized equipment, software, and training. Three-dimensional ultrasound and carotid MRI are not available at every clinic or hospital. The author's "should replace it" recommendation is a call for the field to adopt these methods more widely, not a statement that they are universally available today.

Second, this is a single expert's review article based on the published literature and his own experience. It is not a randomized controlled trial, and it represents one prominent voice in the field. While the evidence supporting plaque measurement is substantial, individual clinicians may reasonably weigh the practical constraints of their own practice settings.

Third, the review focuses on measurement of the carotid arteries. While carotid plaque burden correlates with cardiovascular risk throughout the body, it does not directly visualize plaque in the coronary arteries of the heart or other vascular beds.

Fourth, insurance coverage and healthcare system policies may not yet reimburse for plaque burden measurement in the same way they do for IMT, which could limit access for some patients.

Recommendations for Patients

What does this mean for you, as a patient? Here are practical steps to consider:

• Ask about plaque measurement. If you are at risk for stroke or heart disease—due to high blood pressure, high cholesterol, diabetes, smoking, or a family history—ask your doctor whether a carotid ultrasound that measures plaque area or volume is available and appropriate for you.
• Know your numbers. If you have a carotid plaque measurement, ask what your TPA or TPV is and what it means in terms of your risk. Track it over time if your doctor recommends repeat scanning.
• Treat the arteries, not just the risk factors. The underlying philosophy of this research is that the goal of treatment is to stop the growth of plaque. That means combining medications (such as statins and blood pressure drugs) with lifestyle changes—quitting smoking, eating a plant-forward diet, exercising regularly, and managing stress.
• Be patient with prevention. Plaque regression takes time—typically months to years of consistent treatment. Repeat measurements can help you and your doctor see that the treatment is paying off.
• Ask about clinical trials. Because plaque burden measurement enables faster drug trials, patients with measurable plaque may be eligible for studies of new therapies. These trials can provide access to cutting-edge treatments while contributing to medical knowledge.
• Seek out centers with expertise. If you have severe atherosclerosis or a strong family history, consider asking for a referral to a specialized stroke prevention or vascular prevention clinic that offers advanced plaque imaging.

The bottom line is that measuring plaque burden is a powerful, patient-centered approach to cardiovascular care. Instead of guessing risk from indirect markers, doctors can see the disease itself—and use that information to guide treatment with far greater precision.

Frequently Asked Questions

What is carotid plaque burden and why does it matter?

Carotid plaque burden is the total amount of atherosclerotic plaque in the carotid arteries, which supply blood to the brain. Measuring it helps doctors predict your risk of stroke and heart attack. More plaque means higher risk, and the measurement can guide treatment decisions. It is measured using ultrasound or MRI.

How is carotid plaque burden measured?

There are three main ways: Total Plaque Area (TPA) using standard ultrasound adds up cross-sectional areas of all plaques. Total Plaque Volume (TPV) uses 3D ultrasound to measure plaque volume. Vessel Wall Volume (VWV) uses MRI to measure the entire vessel wall, including early changes before plaque forms. Each method captures different aspects of the disease.

How is plaque burden different from carotid intima-media thickness (IMT)?

IMT measures thickness of the two inner artery wall layers at a single point, which can miss actual plaque. Plaque burden directly measures the plaque itself, making it a stronger predictor of cardiovascular events and better at tracking treatment changes. An expert review concludes plaque burden is far superior and should replace IMT in clinical practice.

What do my plaque burden numbers mean for my risk?

Higher plaque burden indicates a higher risk of stroke and heart attack. If your measurement is high, your doctor may recommend aggressive prevention such as statins, blood pressure control, and lifestyle changes, regardless of cholesterol numbers. If low, you may be at lower risk than blood tests alone suggest, possibly avoiding unnecessary medication.

Can carotid plaque be reduced or reversed?

Yes, with intensive treatment of cardiovascular risk factors, plaque can stabilize and even regress. Repeat measurements of total plaque area or volume can show measurable improvement over months to years. Seeing this improvement can motivate you to continue medication and lifestyle changes. Treatment typically combines medications like statins with smoking cessation, diet, exercise, and stress management.

What should I ask my doctor about plaque measurement?

If you are at risk for stroke or heart disease, ask whether a carotid ultrasound measuring plaque area or volume is available and appropriate for you. Ask what your numbers mean and whether repeat scanning is recommended. You can also ask about clinical trials, as measurable plaque may qualify you for studies of new therapies.

Are there limitations to plaque burden measurement?

Yes. Specialized equipment and training are needed for 3D ultrasound and carotid MRI, which are not available everywhere. The recommendation to replace IMT is a call for wider adoption, not a statement of universal availability. Insurance may not yet cover these measurements. Also, carotid measurements do not directly visualize plaque in coronary arteries.

Can a second opinion change my stroke treatment plan if my doctor only measured carotid intima-media thickness instead of plaque burden?

Carotid intima-media thickness (IMT) is a weaker predictor of cardiovascular events than direct plaque burden measurement. Measuring total plaque area or volume can show whether the disease is active and guide more aggressive prevention, or reveal lower risk than blood tests suggest. If your doctor relies only on IMT or risk calculators, a second opinion can help determine whether plaque burden measurement should be used to guide treatment decisions. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article: Spence JD. Measurement of carotid plaque burden. Current Opinion in Lipidology. 2020 Oct;31(5):291-298.

• Author: J. David Spence
• Affiliation: Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada
• DOI: 10.1097/MOL.0000000000000706
• PMID: 32773468
• Publication type: Peer-reviewed review article indexed in PubMed

This patient-friendly article is based on peer-reviewed research published in a PubMed-indexed journal. Additional resources related to this article, as listed on the PubMed record, include MedGen (a database of human genetics information) and MedlinePlus Health Information (a consumer health resource from the U.S. National Library of Medicine).